STESteris
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. 10-K, Item 1
- Headquarters
- Dublin, L2
- CEO
- Daniel A. Carestio
- Next results
- around Feb 3, 2027
Dilution: new shares, stock pay and buybacks
prospectuses (S-3, 424B) of the last three years and the 10-K cash flow From EDGARNew Nov 6, 2026: Shelf registration: shares and other securities, amount not fixed (S-3ASR) Email me when STE files the next one
Shares offered
Since Nov 11, 2023: 1 shelf registration.
- Nov 6, 2026 Shelf registration: shares and other securities, amount not fixed S-3ASR
Every offering filing →“Under this shelf registration process, we may from time to time sell the following securities in one or more offerings at prices and on other terms to be determined at the time of offering: • senior unsecured debt securities of STERIS plc or STERIS Irish FinCo Unlimited Company (“debt securities”), which may be either guaranteed or not guaranteed; guarantees of debt securities by STERIS plc, STERIS Irish FinCo …”
S-3ASR, Nov 6, 2026 ↗
Diluted shares: 98.70M in the year to Mar 31, 2026 2026 -0.4%2025 -0.3%2024 -0.8%2023 +2.0%
Change in the diluted weighted average share count from the fiscal year before, stock splits taken out. Bars use one scale for stock pay and buybacks. Prospectuses are read from their cover page; preliminary ones are left out. Cash & buybacks, year by year → · How
FY2026, from the cash flow statement in the 10-K, added up.
Came from
| Operating cash flow | $1.3B |
| Shares sold | $32.9M |
Went to
| Capital spending | $369.0M |
| Acquisitions | $20.1M |
| Buybacks | $235.5M |
| Dividends | $241.8M |
| Added to cash | $267.9M |
| Other, net investments bought and sold, other financing and investing lines, and exchange rates |
$240.0M |
Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.
Each CEO's years
The CEO of each fiscal year as named in the proxy's pay versus performance table, and what the 10-Ks show for those years. Facts, not a grade.
Daniel A. Carestio, Walter M Rosebrough
- Operating cash flow
- $1.3B
- Capital spending
- $369.0M
- Acquisitions
- $20.1M
- Buybacks
- $235.5M
- Dividends
- $241.8M
- Stock-based pay
- $61.7M
- Diluted shares since FY2025
- -0.4%
- Revenue since FY2025
- +9%
- Debt since FY2025
- -$112.0M
- CEO pay (reported)
- $11.5M
| Fiscal year to | Buybacks | Dividends | Stock pay | Shares issued for cash | Diluted shares |
|---|---|---|---|---|---|
| 2026-03-31 | $235.5M | $241.8M | $61.7M | $32.9M | 98.70M |
| 2025-03-31 | $211.3M | $219.9M | $57.4M | $25.5M | 99.10M |
| 2024-03-31 | $11.8M | $200.6M | $56.5M | $10.5M | 99.40M |
| 2023-03-31 | $308.6M | $183.5M | $39.0M | $1.8M | 100.25M |
| 2022-03-31 | $55.8M | $163.2M | $57.7M | $10.1M | 98.33M |
From the XBRL of the 10-Ks (cash flow statement and diluted weighted average shares); each year as reported in the latest 10-K that includes it. Concepts: buybacks = PaymentsForRepurchaseOfCommonStock; dividends = PaymentsOfDividendsCommonStock; sbc = ShareBasedCompensation; issuance = ProceedsFromStockOptionsExercised; diluted_shares = WeightedAverageNumberOfDilutedSharesOutstanding.
Work on STE in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/STE/export.csv") into a cell.